We are proud to share that Dr. Freddy T. Nguyen, co-founder and CEO of Nine Diagnostics, has been selected as a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine (NAM).
This prestigious program — supported by the Gordon and Betty Moore Foundation in partnership with the Council of Medical Specialty Societies (CMSS) — recognizes only a handful of health professionals each year who are driving transformative advances in diagnostic quality, safety, and innovation.
Shaping the Future of Diagnostics
As part of the program, Dr. Nguyen will advance a patient-centered framework for diagnostic technology development. His work will address critical challenges in bias, validation, study design, data representation, and clinical implementation — all with the goal of ensuring that next-generation diagnostics are accurate, equitable, and impactful for patients.
“Diagnostics are the foundation of clinical decision-making, yet diagnostic error remains one of the most significant challenges in medicine,” said Dr. Nguyen. “This program is an opportunity to help set a national agenda for how new technologies can improve accuracy, safety, and patient outcomes at scale.”
Recognition of Thought Leadership
The NAM Scholars in Diagnostic Excellence program builds upon the National Academies’ landmark report Improving Diagnosis in Health Care, underscoring diagnosis as a critical national priority. Selection as a Scholar highlights Dr. Nguyen’s leadership at the intersection of science, technology, and patient care — the same vision that drives Nine Diagnostics.
At Nine Diagnostics, we see this recognition as further validation of our mission: to deliver actionable insights from biology that help patients reach the right treatment faster. By combining nanosensor platforms, advanced proteomics and metabolomics, and AI-powered analytics, we are advancing a future where diagnostic excellence is not just a goal, but a standard.